TTS, which clinically simulate heparin-induced thrombocytopenia, is mediated by platelet-activating antibodies against platelet factor 4 (PF4) [26] and, interestingly, is more frequently observed following the first dose of ChAdOx1 (Vaxzevria) [23–25]. Here, PF4 is linked to Thrombocytopenia.